Finished
CyberKnife for Unresectable Renal Tumors
NCT00807339 · Beth Israel Deaconess Medical Center · Updated 21 March 2017
- What is being tested
- Stereotactic radiation; CyberKnife Robotic Radiosurgery System
- For
- Renal Cancer
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 95 years. About 17 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started March 2006, ends 20 Aug 2014. Registered 11 Dec 2008.
- Results
- None posted yet.
In the researchers' words
This is a dose escalation study using the CyberKnife radiotherapy device for small surgical or medically untreatable renal tumors. Patients with renal tumors 5cms or less in diameter will be accrued onto this study. The ability of CyberKnife to ablate these renal tumors and maintain renal function with dose escalation will be assessed.
Sites
- Beth Israel Deaconess Medical CenterBoston, Massachusetts, United States